Daily Multivitamin Delays Biological Aging by Up to 5 Months, Trial Finds

A Neatly Framed signal in a Large Randomized Trial: Multivitamins and Epigenetic Aging

• The report centers on biological aging as a process potentially separable from chronological age, with prior work linking healthier lifestyle choices to slower aging as assessed by biomarkers, including epigenetic clocks.
• The study discussed comes from a large randomized trial framework and investigates whether daily intake of a standard multivitamin could influence measures of biological aging, as captured by epigenetic clocks in the COSMOS cohort.

Participants were drawn from a large sample of COSMOS, with a subset providing biospecimens suitable for epigenetic analyses.

• Design: Randomized, controlled, two-year trial structure embedded within the COSMOS (COcoa Supplement Multivitamins Outcomes Study) platform, examining the effects of dietary supplements on health outcomes and biomarkers.
• Population: Adults with a mean chronological age of approximately 70 years at enrollment.
• Interventions: Random assignment to one of four arms over two years:
• Multivitamin plus cocoa extract
• Cocoa extract plus placebo
• Multivitamin plus placebo
• Placebo alone
• The multivitamin formulation used reflects the Centrum Silver product available in the United States at the trial’s outset, containing vitamins A, C, D3, E, and K, B vitamins, plus minerals such as magnesium, zinc, and calcium, among other nutrients.
• Outcomes assessed: Epigenetic aging measures derived from blood samples, focusing on specific clock biomarkers to evaluate shifts in biological aging relative to placebo.

The remaining three clocks—Horvath, Hannum, and DunedinPACE—did not show a statistically significant effect attributable to the multivitamin.

• Overall effect on epigenetic aging: The multivitamin group showed a slowing effect on two of the five clock measures examined, when compared with the placebo group after two years.
• Quantitative interpretation: The observed slowing equates to an approximate 2.7 to 5.1 months reduction in biological aging over the two-year period, as inferred from the clock comparisons.
• Specific clocks affected: The two “second-generation” epigenetic clocks demonstrating slowing were PCGrimAge and PCPhenoAge.
• Subgroup observation: Participants who began the trial with a higher degree of biological aging relative to their chronological age appeared to derive the greatest benefit from daily multivitamin use, suggesting a potentially differential effect tied to baseline epigenetic age acceleration.
• Overall aging trajectory: The report notes that average biological aging progressed in both treatment arms; however, the rate of increase was notably attenuated in those assigned to the multivitamin, indicating a relative deceleration in aging markers within this group.

• The investigators frame the finding as support for a potential role of a broad-based multivitamin in modulating biological aging among older adults, particularly for those with accelerated epigenetic aging at baseline.
• The authors emphasize that this signal emerged within a long-term, large-scale randomized context and that prior COSMOS-derived observations had suggested other benefits (e.g., cognition; cardiovascular outcomes) from related interventions, a point leveraged to explore possible extensions to aging biomarkers.
• They acknowledge uncertainty regarding generalizability to other broad multivitamin formulations beyond Centrum Silver, noting that extrapolation to different product compositions remains unaddressed by direct data from this trial.

• Formulation-specificity: The study explicitly used a Centrum Silver-type multivitamin; whether similar effects would be observed with other multivitamin compositions remains an open question.
• Clock-specific effects: The reduction in biological aging was not uniform across all epigenetic clocks evaluated; only two second-generation clocks showed significant change, while three clocks did not demonstrate meaningful effects.
• Population characteristics: The analysis centers on older adults with an average age near 70 at baseline; applicability to younger populations or those with different health profiles is not established within this report.
• Magnitude and clinical relevance: While the aging clocks indicate a measurable slowing, the clinical implications of a 2.7–5.1 month shift over two years are not detailed in the source; no direct health outcome endpoints are provided in this summary beyond biomarker changes.
• Temporal scope: Observations span two years, leaving questions about longer-term durability of the epigenetic aging effects and potential late-emerging benefits or diminishing returns.

• Targeted benefits: The finding that individuals with greater baseline biological aging may experience more pronounced improvements could influence considerations for prioritizing subgroups in future studies or interventions.
• Research directions: Investigators plan to deepen analysis using additional epigenetic clocks and to incorporate data from two more large randomized trials testing dietary supplements, aiming to broaden the evidentiary basis for interventions affecting epigenetic aging.
• Need for corroboration: The authors underscore the necessity for further clinical trials to clarify how lifestyle and pharmacologic interventions influence biological aging as measured by epigenetic and other biomarkers.

• Generalizability to non-Centrum Silver formulations remains uncertain due to the study’s specific product use.
• Whether the observed clock changes translate into meaningful long-term health advantages beyond biomarker shifts is not established in the presented content.
• The degree to which observed effects may vary by demographic factors, baseline health status, or concomitant medications requires further study.
• The precise mechanisms by which a standard multivitamin might influence epigenetic aging clocks are not explained in the report and warrant mechanistic inquiry.

• A geriatrics physician commented on the study with cautious optimism, reflecting relief in patients’ inquiries about multivitamin use and acknowledging the evolving nature of evidence in this area.

• The source indicates explicit results for two clocks and non-significant findings for the remaining three, with a clear statement about the differential benefit observed by baseline biological age status.